Vistagen Therapeutics, Inc. (VTGN)
Nasdaq · Healthcare · Biotechnology
$0.2632−6.33%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $11.7M
- 52-week range
- $0.20 – $5.14
- 52-week change
- −92.80%
- EPS (trailing)
- −$1.66
- Analyst rating
- 3.0 Hold
- Next earnings
- Nov 12, 2026
Fiscal year to Mar 2026
- Revenue
- $1.3M (+161.11%)
- Net income
- −$69.7M
- Operating margin
- −5683.7%
- Diluted EPS
- −$1.83
From the company’s annual report on SEC EDGAR.
About Vistagen Therapeutics, Inc.
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial to treat loss of appetite associated with chronic disorders, such as cancer cachexia; and…
Headquarters: South San Francisco, United States · 41 employees · vistagen.com